<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02807129</url>
  </required_header>
  <id_info>
    <org_study_id>PO12140</org_study_id>
    <nct_id>NCT02807129</nct_id>
  </id_info>
  <brief_title>Fragmentation of Elastin as a Biological Marker of Frailty and Impact in Tumor Progression in Elderly Patients With Cancer</brief_title>
  <acronym>AgElOn</acronym>
  <official_title>Fragmentation of Elastin as a Biological Marker of Frailty and Impact in Tumor Progression in Elderly Patients With Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CHU de Reims</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CHU de Reims</source>
  <brief_summary>
    <textblock>
      The aim of the study is to evaluate frailty in patients aged â‰¥ 65 years with cancer. The
      elderly population is very heterogeneous, it is necessary to evaluate these elderly patients
      before treatment to assess the risk-benefit balance. To date, this assessment relies on
      subjective clinical methods often not optimal, and slow to implement. An innovative method of
      evaluation could be the determination of elastin peptides. Indeed, the rate of these
      peptides, which are linked to serious conditions associated with age, rising inexorably with
      age and dose could help determine more objectively the type of treatment to offer older
      patients.

      Expected results : This study will allow better identification of the group of frail elderly
      through more relevant biological marker that clinical assessment, often subjective and not
      available within a period compatible with the treatment of newly diagnosed cancer. This
      biological assessment will also enable optimal management of elderly patients in particular
      by allowing the geriatrician better efficiency.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">January 2024</completion_date>
  <primary_completion_date type="Anticipated">January 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>elastin peptides quantification</measure>
    <time_frame>up to 36 months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>blood withdrawn</intervention_name>
    <arm_group_label>patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>urine collection</intervention_name>
    <arm_group_label>patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  65 years or older

          -  diagnosis of cancer

          -  affiliation to a social security scheme

          -  Signed informed consent for the study and for the collection of biological samples

        Exclusion Criteria:

          -  Patient protected by law (guardianship, trusteeship)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Rachid MAHMOUDI</last_name>
    <phone>326784424</phone>
    <phone_ext>33</phone_ext>
    <email>rmahmoudi@chu-reims.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chu Reims</name>
      <address>
        <city>France</city>
        <state>Reims</state>
        <zip>51092</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Damien JOLLY</last_name>
      <phone>326788472</phone>
      <phone_ext>33</phone_ext>
      <email>djolly@chu-reims.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>June 16, 2016</study_first_submitted>
  <study_first_submitted_qc>June 20, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 21, 2016</study_first_posted>
  <last_update_submitted>October 24, 2019</last_update_submitted>
  <last_update_submitted_qc>October 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Frailty</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

